SCTX - Scribe Therapeutics Inc.
Price:
--
--
|
PRICE TARGET:
$49.00
DETAILS
HIGH:
$60.00
LOW:
$37.00
MEDIAN:
$50.00
CONSENSUS:
$49.00
UPSIDE:
80.75%
About Scribe Therapeutics Inc. (http://www.scribetx.com)
Scribe Therapeutics is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. The company engineers proprietary technologies to target the genetic drivers of disease, with an initial focus on atherosclerotic cardiovascular disease (ASCVD), aiming to shift treatment from chronic care to preventative intervention.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Benjamin L. Oakes | Co-Founder, President, CEO & Chairman | 1989 | $574,976 USD |
| David L. Parrot | CFO & Treasurer | 1969 | $475,827 USD |
| Svetlana Lucas | Chief Business Officer | 1972 | $466,980 USD |
| Brett T. Staahl | Co-Founder & VP of External Innovation | – | – |
| Chitra Sharma | Senior Vice President of Development | – | – |
| David F. Savage | Co-Founder & Scientific Advisor | – | – |
| George Manning | VP & Controller | – | – |
| Jennifer A. Doudna | Co-Founder & Scientific Advisor | 1964 | – |
| Richard Hector | Head of Intellectual Property | – | – |
| Stephen V. Thau | Secretary | – | – |
| Sunny Mok | Senior Vice President of Operations | – | – |